JP2025508435A - Ｅｒｋ５媒介性疾患を治療するのに有用な複素環式化合物 - Google Patents

Ｅｒｋ５媒介性疾患を治療するのに有用な複素環式化合物 Download PDF

Info

Publication number
JP2025508435A
JP2025508435A JP2024548743A JP2024548743A JP2025508435A JP 2025508435 A JP2025508435 A JP 2025508435A JP 2024548743 A JP2024548743 A JP 2024548743A JP 2024548743 A JP2024548743 A JP 2024548743A JP 2025508435 A JP2025508435 A JP 2025508435A
Authority
JP
Japan
Prior art keywords
pharma
solvate
acceptable salt
ceutically acceptable
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508435A5 (cg-RX-API-DMAC7.html
Inventor
バターワース，サム
スミス，オリヴァー・リチャード
エヴァンス，チャールズ・ニコラス・ジョージ
フィネガン，キャサリン・ジョージナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2025508435A publication Critical patent/JP2025508435A/ja
Publication of JP2025508435A5 publication Critical patent/JP2025508435A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024548743A 2022-02-18 2023-02-17 Ｅｒｋ５媒介性疾患を治療するのに有用な複素環式化合物 Pending JP2025508435A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2202199.2 2022-02-18
GBGB2202199.2A GB202202199D0 (en) 2022-02-18 2022-02-18 Compounds
PCT/GB2023/050369 WO2023156791A1 (en) 2022-02-18 2023-02-17 Heterocyclic compounds useful for treating a erk5-mediated disease

Publications (2)

Publication Number Publication Date
JP2025508435A true JP2025508435A (ja) 2025-03-26
JP2025508435A5 JP2025508435A5 (cg-RX-API-DMAC7.html) 2026-01-08

Family

ID=80934460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548743A Pending JP2025508435A (ja) 2022-02-18 2023-02-17 Ｅｒｋ５媒介性疾患を治療するのに有用な複素環式化合物

Country Status (8)

Country Link
US (1) US20250154157A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479400B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508435A (cg-RX-API-DMAC7.html)
CN (1) CN119053604A (cg-RX-API-DMAC7.html)
AU (1) AU2023220934A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251985A1 (cg-RX-API-DMAC7.html)
GB (1) GB202202199D0 (cg-RX-API-DMAC7.html)
WO (1) WO2023156791A1 (cg-RX-API-DMAC7.html)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
WO2015117083A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
EP3099693A4 (en) * 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015129927A1 (en) * 2014-02-26 2015-09-03 Kyorin Pharmaceutical Co., Ltd. Heterocyclic compounds
AU2020356484A1 (en) 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases

Also Published As

Publication number Publication date
AU2023220934A1 (en) 2024-08-29
EP4479400B1 (en) 2026-08-19
GB202202199D0 (en) 2022-04-06
EP4479400A1 (en) 2024-12-25
CA3251985A1 (en) 2023-08-24
US20250154157A1 (en) 2025-05-15
WO2023156791A1 (en) 2023-08-24
CN119053604A (zh) 2024-11-29

Similar Documents

Publication Publication Date Title
JP7762957B2 (ja) Ｍｅｔｔｌ３阻害化合物
US11787786B2 (en) Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
JP2025016684A (ja) Ｐａｒｇ阻害剤としての４－置換インドールおよびインダゾールスルホンアミド誘導体
EP3283484B1 (en) Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity
CN106459035B (zh) N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途
AU2016214132A1 (en) Autotaxin inhibitory compounds
WO2025262192A1 (en) Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
JP2026500923A (ja) 阻害性化合物
CN104968343A (zh) 吲哚衍生物
US20250154157A1 (en) Heterocyclic compounds useful for treating a erk5-mediated disease
JP2024543183A (ja) 阻害剤化合物
WO2025216628A1 (en) Protac compounds
AU2024372123A1 (en) Inhibitory compounds
AU2024369838A1 (en) Inhibitory compounds
HK40011048A (en) Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
HK40011048B (en) Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
HK1224285B (en) Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251031